Investors & Media Home

Mesoblast is a world leader in cell-based medicines.

The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.

These allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammator... More

Latest ASX AnnouncementsMore
16 February 2017
Presentation On Mesoblast RA P2 9 Month Trial Results
16 February 2017
Positive Nine Month RA Results For Mesoblast Cell Therapy
13 February 2017
Published Results Show MSB Cells Effective In RA Model
10 February 2017
Release of shares from voluntary escrow
Latest Press ReleasesMore
24 February 2016
First Allogeneic Cell Therapy Product Launched in Japan by Mesoblast Licensee
NEW YORK and MELBOURNE, Australia, Feb. 24, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MES... 
22 February 2016
Increased Survival Using MSB Cells In Children With aGVHD
17 February 2016
Mesoblast Reports on First Half and Second Quarter Financial Results
MELBOURNE, Australia and NEW YORK, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB) (... 
16 February 2016
MSB Therapy Shows Benefit In First Cohort Of RA Patients
Upcoming EventsMore
There are currently no events scheduled.
Prior to
27 February 2017 9:00 a.m. AEDT
Financial Results for the Second Quarter/Half Year Ended December 31, 2016
Stock QuoteMore
Exchange :ASX
Price :A$1.64
Change : Stock is Down 0.04 (2.38%)
Volume :292,901
Data as of 24 February 2017 4:11 p.m. ET
Data provided by Nasdaq Minimum 15 minutes delay
Download Documentation CEO Presentation to 2016 Annual General Meeting
Download Documentation First Quarter Results Presentation
Download Documentation 2016 Annual Report
Download Documentation 2016 Full Year Results
E-mail Alerts
Sign up to receive e-mail alerts.

Share Price ASX: MSB  AUD 1.64 as of Feb 24, 2017